Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kadunilimab neoadjuvant therapy in resectable esophageal squamous cell carcinoma
ChiCTR2300078478Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Dec 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Pathologic complete response rate and Major pathological response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300078478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078478.